Harvard Medical School; Dana-Farber Cancer Institute
Dr. Wolpin is a medical oncologist and scientist at Dana-Farber Cancer Institute, Brigham and Women’s Hospital and Harvard Medical School. His research program is dedicated to understanding the factors that promote initiation and progression of pancreatic ductal adenocarcinoma, with a focus on defining early detection strategies and personalized treatment approaches for pancreatic cancer. Dr. Wolpin also leads multiple clinical trials that evaluate new therapies for patients with pancreatic cancer. At Dana-Farber, Dr. Wolpin serves as Director of the Gastrointestinal Cancer Center, Director of the Hale Family Center for Pancreatic Cancer Research, and Director of the DFCI-Lustgarten Foundation Dedicated Pancreatic Cancer Research Laboratory. He is also an Associate Professor of Medicine at Harvard Medical School and the Robert T. & Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute. He serves as co-Principal Investigator for the NCI Pancreatic Cancer Cohort Consortium, Chair of the NCI Pancreatic Cancer Detection Consortium, and Vice Chair of the NCI Pancreas Task Force. His research has been funded by the National Cancer Institute, Howard Hughes Medical Institute, Lustgarten Foundation, ASCO Conquer Cancer Foundation, Pancreatic Cancer Action Network, Stand Up to Cancer, and U.S. Department of Defense. Dr. Wolpin’s clinical practice involves the care of patients with gastrointestinal cancers, with a particular focus on pancreatic cancer.